gossypol and Carcinoma, Non-Small Cell Lung studies

gossypol and Carcinoma, Non-Small Cell Lung

Gossypol: A dimeric sesquiterpene found in cottonseed (GOSSYPIUM). The (-) isomer is active as a male contraceptive (CONTRACEPTIVE AGENTS, MALE) whereas toxic symptoms are associated with the (+) isomer.

Research Excerpts

Excerpt	Relevance	Reference
" Unlike trials with continuous daily dosing of AT-101, no cases of small bowel obstruction were reported."	2.76	Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. ( Holmlund, JT; Karaseva, NA; Leopold, L; Luft, AV; Orlov, SV; Popovych, O; Ready, N; Wood, BA, 2011)
"Radiotherapy has a central role in the treatment of lung cancer."	1.36	AT-101, a pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer. ( Chen, H; Kim, KW; Li, B; Lu, B; Moretti, L, 2010)
" The objective of this study was to evaluate the effect of various SPI, both alone and in combination with cisplatin, on three different non-small cell lung cancer (NSCLC) cell lines."	1.35	Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines. ( El-Hefnawy, T; Kilic, A; Landreneau, RJ; Luketich, JD; Schuchert, MJ, 2009)
"Gossypol has wide antineoplastic effects in vitro, but its effects on human lung cancer have not been explored."	1.32	Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line. ( Chang, JS; Chiang, LC; Hsu, YL; Kuo, PL; Lin, CC, 2004)

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (25.00)	29.6817
2010's	9 (75.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

3 (25.00)

29.6817

2010's

9 (75.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Lee, S	1
Lee, JS	2
Seo, J	1
Lee, SH	2
Kang, JH	2
Song, J	1
Kim, SY	2
Mei, H	1
Lin, Z	1
Wang, Y	1
Wu, G	1
Song, Y	1
Ren, T	2
Shan, J	2
Qing, Y	2
Qian, C	2
Li, Q	3
Lu, G	2
Li, M	2
Li, C	2
Peng, Y	2
Luo, H	2
Zhang, S	3
Zhang, W	1
Wang, D	3
Zhou, SF	2
Wang, G	1
Yang, Y	1
Cheng, Y	1
Wei, X	1
Li, Y	1
Duan, W	1
Huang, C	1
Zheng, X	1
Sun, L	1
Luo, J	1
Xin, X	1
Gao, M	1
Nam, B	1
Seong, TW	1
Son, J	1
Jang, H	1
Hong, KM	1
Lee, C	1
Zhao, R	1
Zhou, S	1
Xia, B	1
Zhang, CY	1
Hai, P	1
Zhe, H	1
Wang, YY	1
Kilic, A	1
Schuchert, MJ	1
Luketich, JD	1
Landreneau, RJ	1
El-Hefnawy, T	1
Moretti, L	1
Li, B	1
Kim, KW	1
Chen, H	1
Lu, B	1
Ready, N	1
Karaseva, NA	1
Orlov, SV	1
Luft, AV	1
Popovych, O	1
Holmlund, JT	1
Wood, BA	1
Leopold, L	1
Chang, JS	1
Hsu, YL	1
Kuo, PL	1
Chiang, LC	1
Lin, CC	1
Yeow, WS	1
Baras, A	1
Chua, A	1
Nguyen, DM	2
Sehgal, SS	1
Schrump, DS	1

Studies

Lee, S

Lee, JS

Seo, J

Lee, SH

Kang, JH

Song, J

Kim, SY

Mei, H

Lin, Z

Wang, Y

Wu, G

Song, Y

Ren, T

Shan, J

Qing, Y

Qian, C

Li, Q

Lu, G

Li, M

Li, C

Peng, Y

Luo, H

Zhang, S

Zhang, W

Wang, D

Zhou, SF

Wang, G

Yang, Y

Cheng, Y

Wei, X

Li, Y

Duan, W

Huang, C

Zheng, X

Sun, L

Luo, J

Xin, X

Gao, M

Nam, B

Seong, TW

Son, J

Jang, H

Hong, KM

Lee, C

Zhao, R

Zhou, S

Xia, B

Zhang, CY

Hai, P

Zhe, H

Wang, YY

Kilic, A

Schuchert, MJ

Luketich, JD

Landreneau, RJ

El-Hefnawy, T

Moretti, L

Li, B

Kim, KW

Chen, H

Lu, B

Ready, N

Karaseva, NA

Orlov, SV

Luft, AV

Popovych, O

Holmlund, JT

Wood, BA

Leopold, L

Chang, JS

Hsu, YL

Kuo, PL

Chiang, LC

Lin, CC

Yeow, WS

Baras, A

Chua, A

Nguyen, DM

Sehgal, SS

Schrump, DS

Clinical Trials (1)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Double Blind, Placebo-controlled Multiple-center Phase III Trial of Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression[NCT01977209]	Phase 3	204 participants (Anticipated)	Interventional	2013-09-30	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial

Phase

Enrollment

Study Type

Start Date

Status

A Randomized, Double Blind, Placebo-controlled Multiple-center Phase III Trial of Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression[NCT01977209]

Phase 3

204 participants (Anticipated)

Interventional

2013-09-30

Recruiting

[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for gossypol and Carcinoma, Non-Small Cell Lung

Article	Year
Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Prot	2011

Article

Year

Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:4

Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Prot

2011

Other Studies

11 other studies available for gossypol and Carcinoma, Non-Small Cell Lung

Article	Year
Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC. Scientific reports, 2018, 10-24, Volume: 8, Issue:1 Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Dr	2018
Autophagy inhibition enhances pan-Bcl-2 inhibitor AT-101-induced apoptosis in non-small cell lung cancer. Neoplasma, 2014, Volume: 61, Issue:2 Topics: Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; G	2014
Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway. Drug design, development and therapy, 2014, Volume: 8 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Proliferation;	2014
Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer. Drug design, development and therapy, 2015, Volume: 9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung;	2015
Prediction of survival prognosis of non-small cell lung cancer by APE1 through regulation of Epithelial-Mesenchymal Transition. Oncotarget, 2016, May-10, Volume: 7, Issue:19 Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, T	2016
Aldehyde dehydrogenase inhibition combined with phenformin treatment reversed NSCLC through ATP depletion. Oncotarget, 2016, Aug-02, Volume: 7, Issue:31 Topics: Action Potentials; Adenosine Triphosphate; Aldehyde Dehydrogenase; Animals; Aspartic Acid; Carcinoma	2016
AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations. BMC cancer, 2016, 07-18, Volume: 16 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung	2016
Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines. The Journal of surgical research, 2009, Jun-01, Volume: 154, Issue:1 Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Chromones; Cisplatin; Cyclooxygenase In	2009
AT-101, a pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Ga	2010
Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line. Clinical and experimental pharmacology & physiology, 2004, Volume: 31, Issue:10 Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 8; Caspases; Cell Cycle Proteins; Cell Line, Tumo	2004
Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. The Journal of thoracic and cardiovascular surgery, 2006, Volume: 132, Issue:6 Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Death; Esophageal Neoplasms; Gossypol; Humans; Lung	2006

Article

Year

Targeting Mitochondrial Oxidative Phosphorylation Abrogated Irinotecan Resistance in NSCLC.

Scientific reports, 2018, 10-24, Volume: 8, Issue:1

Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Dr

2018

Autophagy inhibition enhances pan-Bcl-2 inhibitor AT-101-induced apoptosis in non-small cell lung cancer.

Neoplasma, 2014, Volume: 61, Issue:2

Topics: Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; G

2014

Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway.

Drug design, development and therapy, 2014, Volume: 8

Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Proliferation;

2014

Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.

Drug design, development and therapy, 2015, Volume: 9

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung;

2015

Prediction of survival prognosis of non-small cell lung cancer by APE1 through regulation of Epithelial-Mesenchymal Transition.

Oncotarget, 2016, May-10, Volume: 7, Issue:19

Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, T

2016

Aldehyde dehydrogenase inhibition combined with phenformin treatment reversed NSCLC through ATP depletion.

Oncotarget, 2016, Aug-02, Volume: 7, Issue:31

Topics: Action Potentials; Adenosine Triphosphate; Aldehyde Dehydrogenase; Animals; Aspartic Acid; Carcinoma

2016

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.

BMC cancer, 2016, 07-18, Volume: 16

Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung

2016

Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines.

The Journal of surgical research, 2009, Jun-01, Volume: 154, Issue:1

Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Chromones; Cisplatin; Cyclooxygenase In

2009

AT-101, a pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:5

Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Ga

2010

Upregulation of Fas/Fas ligand-mediated apoptosis by gossypol in an immortalized human alveolar lung cancer cell line.

Clinical and experimental pharmacology & physiology, 2004, Volume: 31, Issue:10

Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 8; Caspases; Cell Cycle Proteins; Cell Line, Tumo

2004

Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.

The Journal of thoracic and cardiovascular surgery, 2006, Volume: 132, Issue:6

Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Death; Esophageal Neoplasms; Gossypol; Humans; Lung

2006